Literature DB >> 25041333

The efficacy of long-term psychodynamic psychotherapy, fluoxetine and their combination in the outpatient treatment of depression.

Andre Goettems Bastos1, Luciano Santos Pinto Guimaraes, Clarissa Marceli Trentini.   

Abstract

OBJECTIVE: There are few randomized controlled trials examining the efficacy of long-term psychodynamic psychotherapy (LTPP) in depression treatment. LTPP was compared with fluoxetine treatment and their combination;
METHODS: 272 depressed patients (aged 26-34, 72% with a first episode of depression) were randomized to receive LTPP (one session/week), fluoxetine treatment (20-60 mg/day) or their combination for 24 months. Beck Depression Inventory (BDI) was the outcome measure. The psychotherapy was not manualized and the treatment took place under real-life conditions in an outpatient psychiatric clinic.
RESULTS: Intention-to-treat analyses indicated that all the treatments were associated with significant reductions in the BDI scores (mean reduction of 18.88 BDI points). Furthermore, LTPP and combination therapy were more effective in reducing BDI scores than fluoxetine alone (22.08 and 22.04 vs. 12.53 BDI points).
CONCLUSIONS: LTPP, pharmacological treatment with fluoxetine and their combination are effective in reducing symptoms of patients with moderate depression. LTPP and combined treatment were more effective compared to fluoxetine alone. These findings have implications for patients with depression who may benefit from long-term psychotherapy or combined treatment, or for depressed patients who do not wish to take medications such as fluoxetine.

Entities:  

Keywords:  depression; fluoxetine; long-term psychodynamic psychotherapy

Mesh:

Substances:

Year:  2014        PMID: 25041333     DOI: 10.1080/10503307.2014.935519

Source DB:  PubMed          Journal:  Psychother Res        ISSN: 1050-3307


  5 in total

1.  The effectiveness of psychodynamic psychotherapies: An update.

Authors:  Peter Fonagy
Journal:  World Psychiatry       Date:  2015-06       Impact factor: 49.548

2.  Neuroprotective Effects of Fluoxetine Against Chronic Stress-Induced Neural Inflammation and Apoptosis: Involvement of the p38 Activity.

Authors:  Yuxiao Zhao; Pan Shang; Meijian Wang; Min Xie; Jian Liu
Journal:  Front Physiol       Date:  2020-05-11       Impact factor: 4.566

3.  Predictors of response in the treatment of moderate depression.

Authors:  Andre G Bastos; Luciano S Guimarães; Clarissa M Trentini
Journal:  Braz J Psychiatry       Date:  2016-11-24       Impact factor: 2.697

4.  Psychotherapy or medication for depression? Using individual symptom meta-analyses to derive a Symptom-Oriented Therapy (SOrT) metric for a personalised psychiatry.

Authors:  Nils Kappelmann; Martin Rein; Julia Fietz; Helen S Mayberg; W Edward Craighead; Boadie W Dunlop; Charles B Nemeroff; Martin Keller; Daniel N Klein; Bruce A Arnow; Nusrat Husain; Robin B Jarrett; Jeffrey R Vittengl; Marco Menchetti; Gordon Parker; Jacques P Barber; Andre G Bastos; Jack Dekker; Jaap Peen; Martin E Keck; Johannes Kopf-Beck
Journal:  BMC Med       Date:  2020-06-05       Impact factor: 8.775

5.  Potentiation of Schaffer-Collateral CA1 Synaptic Transmission by eEF2K and p38 MAPK Mediated Mechanisms.

Authors:  Weiguang Weng; Ying Chen; Man Wang; Yinghan Zhuang; Thomas Behnisch
Journal:  Front Cell Neurosci       Date:  2016-10-25       Impact factor: 5.505

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.